Search Thermo Fisher Scientific
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
FIGURE: 1 / 1
Pembrolizumab Antibody (A01844-40) in ELISA
Anti-Pembrolizumab antibody (GenScript, A01844-40) binds with Pembrolizumab. While the antibody does not recognize the human IgG Fc fragment (data not shown). Coating antigen: Pembrolizumab, 1 µg/mL. Anti-Pembrolizumab antibody (GenScript, A01844-40) dilution start from 1,000 ng/mL, EC50= 2.58 ng/mL.
Product Details
A01844-40
Product Specifications
Species Reactivity
Human
Host/Isotype
Mouse
/ IgG1, kappa
Class
Monoclonal
Type
Antibody
Clone
1D6E10
Immunogen
Pembrolizumab
Conjugate
Form
Lyophilized
Purification
Protein A
Storage buffer
PBS, pH 7.4
Contains
0.02% sodium azide
Storage conditions
-20°C or -80°C if preferred
Shipping conditions
Ambient (domestic); Wet ice (international)
Product Specific Information
Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.
Pembrolizumab (Keytruda) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Pembrolizumab binds to the human cell surface receptor PD-1 (Programmed Cell Death Protein 1) and blocks its interaction with PD-L1, resulting in the activation of T-cell-mediated immune responses against tumor cells. GenScript Anti-Pembrolizumab Antibody (1D6E10), mAb, Mouse is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Pembrolizumab.
Target Information
Pembrolizumab (Keytruda) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Pembrolizumab binds to the human cell surface receptor PD-1 (Programmed Cell Death Protein 1) and blocks its interaction with PD-L1, resulting in the activation of T-cell-mediated immune responses against tumor cells.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
References (0)
Have you cited this product in a publication?
Let us know so we can reference it here.
Bioinformatics
Protein Aliases: Keytruda; MK-3475
Performance Guarantee
If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Learn more
We're here to help
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support